Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We triggered acute hyperlipidemia in aged and young mice by inducing liver-specific degradation of the LDL receptor combined with a 10-week western diet and found that atherogenesis was enhanced in aged WT mice.
|
31818196 |
2020 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
LDLR KO along with LDLR/apoE double KO rabbits should provide a novel means for translational investigations of human hyperlipidemia and atherosclerosis.
|
30885208 |
2019 |
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Biological samples refining: Collection 1 (primary hypercholesterolemia suspected) included unrelated individuals with hyperlipidaemia and without LDLR, APOB and PCSK9 gene mutations (Set 1), and Collection 2 (LSD suspected) included individuals without definitive LSD diagnosis (Set 2).
|
31004967 |
2019 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is a severe genetic hyperlipidemia characterized by increased levels of low-density lipoprotein cholesterol (LDL-C), leading to premature atherosclerosis.
|
30827231 |
2019 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Dietary Palmitoleic Acid Attenuates Atherosclerosis Progression and Hyperlipidemia in Low-Density Lipoprotein Receptor-Deficient Mice.
|
30921498 |
2019 |
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
LDL-associated LPA was increased in plasma from high-fat Western diet-fed mice that are genetically prone to hyperlipidemia (LDL receptor knockout or activated proprotein convertase subtilisin/kexin type 9-overexpressing C57Bl6).
|
31484695 |
2019 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is a genetic hyperlipidemia characterized by elevated concentrations of plasma LDL cholesterol.
|
30700805 |
2019 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, most of the experimental animal models with LDLR deficiency could not fully recapitulate FH because they develop hyperlipidemia and atherosclerosis only in homozygous, but not in heterozygous, form.
|
31323736 |
2019 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Familial hypercholesterolemia (FH) is a primary hyperlipemia.
|
31689621 |
2019 |
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These results implied that the enhanced effect of the combination of berberine with resveratrol on lipid-lowering may be associated with upregulation of low-density-lipoprotein receptor, and could be an effective therapy for hyperlipidemia in some obese-associated disease, such as type II diabetes and metabolic syndrome.
|
30563192 |
2018 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Hepatic NPC1L1 promotes hyperlipidemia in LDL receptor deficient mice.
|
29601818 |
2018 |
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The current study revealed that M3 and its structurally modified analog, A8, could regulate hepatic LDLR and PCSK9 expression to exert lipid-lowering effects via the ERK signal pathway, while A8 showed a stronger effect and might be a promising drug candidate against hyperlipidemia.
|
30335889 |
2018 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate that the Ldlr KO hamster is an animal model of choice for human FH and has great potential in translational research of hyperlipidemia and coronary heart disease.
|
29289533 |
2018 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We further obtained NOD mice deficient in both LDLR and ApoE, and assessed the severity of atherosclerosis and immune response to hyperlipidemia in comparison to ApoE-deficient C57BL/6 mice.
|
30305306 |
2018 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We describe two novel immunodeficient mouse models of hyperlipidemia (Rag1<sup>-/</sup><sup>-</sup>/LDLR<sup>-/</sup><sup>-</sup> and Rag1<sup>-/</sup><sup>-</sup>/ApoE (apolipoprotein E)<sup>-/</sup><sup>-</sup> mice) in addition to established immunocompetent LDLR<sup>-/</sup><sup>-</sup> and ApoE<sup>-/</sup><sup>-</sup> mice.
|
28759039 |
2017 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
The strongest associations for lipid levels change were detected at LPL, TRIB1, APOA1-C3-A4-A5, LIPC, CETP, and LDLR (P range from 4.84×10(-4) to 4.62×10(-18)), whereas LPL, TRIB1, ABCA1, APOA1-C3-A4-A5, CETP, and APOE displayed significant strongest associations for incident hyperlipidemia (P range from 1.20×10(-3) to 4.67×10(-16)).
|
26582766 |
2016 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, plasma lipid concentration lowering effects of PB-liposome/G5-PEG were evaluated in vivo in a LDLR-/- hyperlipidemia mouse model.
|
25587935 |
2015 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
CTD_human |
Bisphenol A exposure induces metabolic disorders and enhances atherosclerosis in hyperlipidemic rabbits.
|
25619500 |
2015 |
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
BBR activates hepatic Raf-1 signaling and up-regulates LDL receptor expression in a rat model of hyperlipidemia with no impact on liver Ras activity.
|
25196457 |
2014 |
Hyperlipidemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Several novel therapies have been introduced for the treatment of people with genetic defects that result in loss of function within the LDL receptor, a major determinant of inherited hyperlipidaemias.
|
25131980 |
2014 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Herein, in low-density lipoprotein receptor-deficient hyperlipidemic and streptozotozin-induced diabetic mice, hyperglycemia and hyperlipidemia acted reciprocally, accentuating renal injury and altering renal function.
|
23318573 |
2013 |
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Chow-fed hypomorphic Apoe mice deficient in low-density lipoprotein receptor expression (Apoe(h/h)Ldlr(-/-)Mx1-cre mice) develop hyperlipidemia and atherosclerosis.
|
23788760 |
2013 |
Hyperlipidemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In experimental animal models of FH, LDLr overexpression following viral vector-based gene transfer has been shown to be associated with long-term stable correction of hyperlipidemia, with attenuation of atherosclerosis progression, and in certain cases even with lesion regression.
|
21774774 |
2011 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Conversely, absence of SREBP-1 suppressed Western diet-induced hyperlipidemia in LDLR-deficient mice and ameliorated atherosclerosis.
|
21546605 |
2011 |
Hyperlipidemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent studies on LDL receptor-deficient mice that are hyperglycemic, but exhibit no marked dyslipidemia compared with nondiabetic controls, show that diabetes in the absence of diabetes-induced hyperlipidemia is associated with an accelerated formation of atherosclerotic lesions, similar to what is seen in fat-fed nondiabetic mice.
|
17395883 |
2007 |